Novel Technologies for Dipeptide Drugs Design and their Implantation.
Review of earlier studies · 2018
- What was studied
- Developer account of medicinal-chemistry programs
- Main finding
- The developers distinguish drug-inspired peptide design (Noopept and Dilept) from mimicking peptide/protein turns (GB-115 and GK-2). This is a historical design framework, not evidence of a shared clinical effect.
Study data at a glance
- Participants or experimental model
- Developer account of medicinal-chemistry programs
- Reported results
- The developers distinguish drug-inspired peptide design (Noopept and Dilept) from mimicking peptide/protein turns (GB-115 and GK-2). This is a historical design framework, not evidence of a shared clinical effect.
Study limitations and source details
Study limitations
- Developer review; claims require appraisal of each original study.
- A shared design method does not establish equivalent biology or clinical benefit.
Source details
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Abstract reviewed
Sources checked
Citation
Gudasheva TA, Ostrovskaya RU, Seredenin SB. Novel Technologies for Dipeptide Drugs Design and their Implantation. Current pharmaceutical design
Study source ↗ · DOI 10.2174/1381612824666181008105641 · Bibliography entry · Link to this summary
Related compounds
NGF mimetics: GK & GTS series
A family of experimental peptides designed from exposed loops of nerve growth factor. Related structures can differ in cell survival, differentiation and pain responses.
CPG & GZK-111
Cycloprolylglycine (CPG) is a naturally occurring cyclic dipeptide formed from proline and glycine. GZK-111 is an experimental linear precursor. CPG has also been measured as a metabolite of Noopept.
Noopept
Omberacetam (GVS-111), a synthetic derivative of the Pro–Gly dipeptide. Its chemical name is N-phenylacetyl-L-prolylglycine ethyl ester. Studies examined cognition and the metabolite cycloprolylglycine.
Dilept
GZR-123, an experimental peptidomimetic designed from a fragment of neurotensin, a signaling peptide. Human studies included psychiatric dose-finding and a comparison with risperidone.
GB-115 & CCK analogues
A synthetic dipeptide derivative containing L-tryptophan, designed from cholecystokinin tetrapeptide (CCK-4). Human anxiety trials studied the oral formulation Ranquilon.